Fresenius Kabi Launches First US Foscavir Rival
Generic Foscarnet Sodium For Injection Available In US Immediately
Executive Summary
Fresenius Kabi has launched the first-ever generic version of Pfizer’s Foscavir in the US, with the product available immediately.
You may also be interested in...
Fresenius Kabi: No Launches From US Melrose Park Facility In 2021
Fresenius Kabi saw a sales and earnings slump in its North America business in the final quarter of last year, which dragged heavily on the firm’s full-year operations. Management have conceded that one of those factors, manufacturing issues at its Melrose Park facility, will blow into 2021, with no product approvals or launches anticipated from the site.
Five Competitors Confirmed On Canadian Adalimumab
Multiple competitors have now confirmed the launch of Canadian biosimilar versions of the world’s biggest-selling drug, Humira.
Kelix Strikes A Deal To Acquire 14 Oncology Injectables
Kelix bio has announced two deals to expand its presence in Africa. The company is set to acquire 14 oncology injectable products from Germany-based Vitane. Furthermore, Kelix has acquired Pharmaceutical Institute, a pharmaceutical company established in Rabat, to enter Morocco. The pan-African company has also invested in Malta.